Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Last year, sales of Herceptin were flat overall at around $7bn, but fell 16% in Europe and Japan as biosimilars started to gather momentum. ... Perjeta has been growing strongly – rising a third to $2.8bn last year – thanks to data showing it

Seattle Genetics wins FDA priority review for oral HER2 drug

Roche dominates the HER2 market, with a portfolio of products that includes Herceptin, Kadcyla and Xeloda. ... breast cancer patients who have received prior treatment with a taxane and Herceptin.

20 for 2020 – Five pharma companies to watch

use in patients who relapse after or don’t respond to Herceptin, so why the excitement about DS-8201? ... treatment pathway in HER2-positive breast cancer as quickly as possible, challenging Roche’s duo of Herceptin and Perjeta (pertuzumab).

Roche posts minor sales miss in Q4 as biosimilar pressure grows

All told, the Swiss group’s pharma sales came in at CHF 12bn ($12.35bn), with its ‘big three’ antibodies – Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab) – all on the ... Perjeta – used as an add-on to

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]